COLUMBIA, Md., Sept. 12 /PRNewswire/ -- Cylex Incorporated, a life sciences company and leader in immune function testing, today announced study results on the effectiveness of ImmuKnow® in minimizing the risk of infection and rejection in post-transplant patients. Testing with ImmuKnow enables doctors to tailor immunosuppressant drug regimens to prevent organ rejection while avoiding infection.
